Multiple Sclerosis Clinical Trials in San Jose, CA

22 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study	Phase 2	Darcy Krueger	16 mi
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO	Phase 1	National Cancer Institute (NCI)	16 mi
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy	Phase 1/2	UniQure Biopharma B.V.	16 mi
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)	Phase 3	National Institute of Allergy and Infectious Diseases (NIAID)	16 mi
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis	Phase 1	Stanford University	16 mi
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases	Phase 1	Kite, A Gilead Company	16 mi
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers	Phase 1/2	Ashvattha Therapeutics, Inc.	17 mi
A Study of AZD0120 in Autoimmune Diseases	Phase 1	AstraZeneca	17 mi
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis	Phase 1	Hoffmann-La Roche	17 mi
Obe-cel in Refractory Progressive Forms of Multiple Sclerosis	Phase 1	Autolus Limited	22 mi
TSC Biosample Repository and Natural History Database	—	National Tuberous Sclerosis Association	39 mi
Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)	—	University of California, San Francisco	42 mi
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk	—	TG Therapeutics, Inc.	42 mi
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis	Phase 2	Novartis Pharmaceuticals	42 mi
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS	Phase 2	PhenoNet, Inc.	42 mi
ECoG BMI for Motor and Speech Control	N/A	Karunesh Ganguly	42 mi
"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS	—	University of California, San Francisco	42 mi
Study of COYA 302 for the Treatment of ALS	Phase 2	Coya Therapeutics	42 mi
Care in Multiple Sclerosis (MS)	—	NYU Langone Health	42 mi
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy	Phase 1/2	University of California, San Francisco	42 mi
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)	Phase 2	University of California, San Francisco	42 mi
Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis	Phase 2	Ari Green	42 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.